标准化肛周瘘管型克罗恩病新疗法临床试验实施的推荐意见
该推荐意见采用RAND/UCLA适宜性方法,由15名国际专家经两轮投票对292条陈述进行评分,其中156条(53.4%)被认为适宜并形成推荐。推荐涉及试验入选应基于临床和影像学标准、主要疗效终点应根据治疗阶段采用临床与影像学联合或复合终点,并指出影像学缓解定义尚存不确定性。
要点
- 试验入选应同时依据临床和影像学标准,且筛查时患者需有最低程度的临床疾病活动。
- 主要疗效终点应根据诱导期或维持期采用临床与影像学联合或复合终点。
- 肛周积液无论大小均被视为与影像学缓解不一致。
核心结论
- 这些推荐意见可能有助于标准化研究设计与实施,并促进针对肛周瘘管型克罗恩病急需疗法的临床开发。
研究设计与样本
- 采用RAND/UCLA适宜性方法制定框架,由15名胃肠病学家、放射学家和结直肠外科医生组成的国际专家小组进行两轮投票评分。
主要发现
- 最终调查共评估292条陈述,其中156条(53.4%)被认为适宜并构成推荐基础。
- 试验入选应基于临床和影像学标准,且患者在筛查时需表现出最低程度的临床疾病活动。
- 主要疗效终点应根据治疗阶段(诱导期 vs 维持期)采用临床和影像学评估的联合主要终点或复合终点。
- 关于影像学缓解的定义存在不确定性,但任何大小的肛周积液均被认为与影像学缓解不一致。
关键数值与推荐
- 调查陈述的中位评分1至≤3.5、>3.5至<6.5、≥6.5至9分别对应不适宜、不确定和适宜。
- 156条(53.4%)陈述被认为适宜。
临床怎么用
- 临床试验设计时应同时采用临床和影像学标准入选患者,并确保筛查时存在最低临床疾病活动。
- 根据诱导期或维持期选择临床与影像学联合主要终点或复合终点作为主要疗效终点。
- 评估影像学缓解时,任何大小的肛周积液均不应视为影像学缓解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Perianal fistulizing Crohn's disease (PFCD) is a potentially debilitating condition with few systematically evaluated treatment options. We aimed to develop expert recommendations to standardize study design and conduct of randomized controlled trials of medical therapy for patients with PFCD. METHODS: We utilized a RAND/UCLA appropriateness method to develop a framework for conducting randomized controlled trials of medical therapy in PFCD. An expert international panel of 15 gastroenterologists, radiologists, and colorectal surgeons rated the appropriateness of survey statements in 2 rounds of voting. Median scores of 1 to ≤3.5, >3.5 to <6.5 and ≥6.5 to 9 on survey statements reflected panel ratings of inappropriate, uncertain, and appropriate, respectively. RESULTS: A total of 292 statements were rated in the final survey, of which 156 (53.4%) were considered appropriate and formed the basis for recommendations. Trial eligibility should be decided based on both clinical and radiological criteria and patients should exhibit a minimum degree of clinical disease activity at screening. The primary efficacy outcome should be either a co-primary or composite endpoint of clinical and radiological assessments depending on treatment phase (induction vs maintenance), recognizing that clinical endpoints are meaningful for patients and radiological outcomes are essential to objectively capture the burden of disease. There was uncertainty regarding definition of radiological remission, but presence of a perianal fluid collection of any size was considered inconsistent with radiologic remission. CONCLUSIONS: These recommendations may help to standardize study design and conduct and foster clinical development of much needed therapies for this debilitating manifestation of Crohn's disease.
引用
- Vuyyuru SK, Hanzel J, Brar MS, et al. Recommendations to Standardize the Conduct of Clinical Trials Evaluating Novel Therapies for Perianal Fistulizing Crohn's Disease. Clin Gastroenterol Hepatol. 2025. PMID: 41265547. doi:10.1016/j.cgh.2025.11.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。